Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-04-07 6:52 pm Sale |
2025-04-03 | 13G | Aldeyra Therapeutics, Inc. ALDX |
PERCEPTIVE ADVISORS LLC | 4,875,851 8.200% |
-4,400,000 (-47.44%) |
Filing History |
| 2025-04-03 4:18 pm Unchanged |
2025-03-31 | 13G | Ensysce Biosciences, Inc. ENSC |
PERCEPTIVE ADVISORS LLC | 86,666 5.300% |
0 (Unchanged) |
Filing History |
| 2025-03-31 4:10 pm Purchase |
2025-03-24 | 13G | Opus Genetics, Inc. IRD |
PERCEPTIVE ADVISORS LLC | 4,510,501 9.990% |
4,510,501 (New Position) |
Filing History |
| 2025-03-26 4:56 pm Purchase |
2024-12-13 | 13G | Inventiva S.A. IVA |
PERCEPTIVE ADVISORS LLC | 5,555,555 5.800% |
5,555,555 (New Position) |
Filing History |
| 2025-03-25 6:29 pm Unchanged |
2025-03-21 | 13D | Trinity Biotech plc TRIB |
PERCEPTIVE ADVISORS LLC | 85,800,000 19.800% |
0 (Unchanged) |
Filing History |
| 2025-02-28 9:15 pm Purchase |
2025-01-08 | 13G | Outset Medical, Inc. OM |
PERCEPTIVE ADVISORS LLC | 375,000 9.500% |
250,774 (+201.87%) |
Filing History |
| 2025-02-21 5:57 pm Purchase |
2025-02-13 | 13G | Edgewise Therapeutics, Inc. EWTX |
PERCEPTIVE ADVISORS LLC | 5,164,487 5.500% |
5,164,487 (New Position) |
Filing History |
| 2025-02-21 4:15 pm Purchase |
2025-02-19 | 13D | Solid Biosciences Inc. SLDB |
PERCEPTIVE ADVISORS LLC | 11,934,679 15.600% |
5,000,001 (+72.10%) |
Filing History |
| 2025-02-14 4:15 pm Purchase |
2024-12-31 | 13D | Trinity Biotech plc TRIB |
PERCEPTIVE ADVISORS LLC | 85,800,000 20.900% |
29,800,000 (+53.21%) |
Filing History |
| 2025-02-14 4:15 pm Purchase |
2024-12-31 | 13G | Surrozen, Inc. SRZN |
PERCEPTIVE ADVISORS LLC | 166,666 5.100% |
166,666 (New Position) |
Filing History |
| 2025-02-14 4:15 pm Purchase |
2024-12-31 | 13G | Ensysce Biosciences, Inc. ENSC |
PERCEPTIVE ADVISORS LLC | 86,666 0.400% |
86,666 (New Position) |
Filing History |
| 2025-02-14 4:15 pm Purchase |
2024-12-31 | 13G | RAPT Therapeutics, Inc. RAPT |
PERCEPTIVE ADVISORS LLC | 5,880,000 4.500% |
3,740,050 (+174.77%) |
Filing History |
| 2025-02-14 4:15 pm Sale |
2024-12-31 | 13G | Contineum Therapeutics, Inc. Class A Common Stock CTNM |
PERCEPTIVE ADVISORS LLC | 1,441,249 5.600% |
-125,420 (-8.01%) |
Filing History |
| 2025-02-14 4:15 pm Unchanged |
2024-12-31 | 13G | Biodesix, Inc. BDSX |
PERCEPTIVE ADVISORS LLC | 6,673,880 4.500% |
0 (Unchanged) |
Filing History |
| 2025-02-14 4:15 pm Sale |
2024-12-31 | 13G | Applied Therapeutics, Inc. APLT |
PERCEPTIVE ADVISORS LLC | 2,860,000 2.400% |
-7,145,000 (-71.41%) |
Filing History |
| 2025-02-14 4:15 pm Purchase |
2024-12-31 | 13G | Forte Biosciences, Inc. FBRX |
PERCEPTIVE ADVISORS LLC | 163,935 2.500% |
12,502 (+8.26%) |
Filing History |
| 2025-02-14 4:15 pm Sale |
2024-12-31 | 13G | Spyre Therapeutics, Inc. SYRE |
PERCEPTIVE ADVISORS LLC | 2,574,723 4.400% |
-297,824 (-10.37%) |
Filing History |
| 2025-02-14 4:15 pm Purchase |
2024-12-31 | 13G | Celcuity Inc. CELC |
PERCEPTIVE ADVISORS LLC | 2,362,279 6.400% |
880,979 (+59.47%) |
Filing History |
| 2025-02-14 4:15 pm Sale |
2024-12-31 | 13G | Amicus Therapeutics, Inc. FOLD |
PERCEPTIVE ADVISORS LLC | 24,245,952 8.100% |
-3,811,504 (-13.58%) |
Filing History |
| 2025-02-14 4:15 pm Purchase |
2024-12-31 | 13G | Amylyx Pharmaceuticals, Inc. AMLX |
PERCEPTIVE ADVISORS LLC | 6,774,348 7.900% |
2,315,607 (+51.93%) |
Filing History |